Quetiapine Fumarate (Quetiapine Fumarate)

Trade Name : Quetiapine fumarate

Bryant Ranch Prepack

TABLET, FILM COATED

Strength 200 mg/1

QUETIAPINE FUMARATE Atypical Antipsychotic [EPC]

Delivery Process

Submit a Request

You can fill in a request for your medicine through the form provided. You can access the form by clicking on the ‘Get Price’ button.

We’ll Get in Touch

Once we review your request, we’ll send you an estimated price for the medicine within 2-5 days.

Confirmation and Payment

You can fill in a request for your medicine through the form provided. You can access the form by clicking on the ‘Get Price’ button.

Submit a Request

You can fill in a request for your medicine through the form provided. You can access the form by clicking on the ‘Get Price’ button.

Product information is meant for

Wholesalers Suppliers Exporters Doctors MOH Tender Supplies Hospitals Brand CROs Comparator Supplies Generic Cooperate Sourcing Individual Patients Indian Institutional Buyers

Disclaimer

Trade Marks displayed in compliance with provisions of: Trademark Act, 1999 u/s 30 and 30 (1) of "Fair use"

GNH India is WHO GDP and ISO 9001 2015 Certified Pharmaceutical Wholesaler/ Supplier/ Exporters/ Importer from India of Quetiapine Fumarate (Quetiapine Fumarate) which is also known as Quetiapine fumarate and Manufactured by Bryant Ranch Prepack. It is available in strength of 200 mg/1 per ml. Read more

Quetiapine Fumarate (Quetiapine Fumarate) is supplied for Tenders/ Emergency imports/ Un - licensed, Specials, Orphan drug/ Name patient line/ RLD supplies/ Reference listed drugs/ Comparator Drug/ Bio-Similar/ Innovator samples For Clinical trials.  Click to know price.     Read less

Packaging and Delivery

Validated Cold Chain Shipment

We deliver your medicines through a validated cold chain shipment process. This process is used as these medicines need to manufactured, transported and stored at very specific temperatures, utilizing thermal and refrigerated packaging methods.

Inquire directly from our website and get 5% off on any medicine!

We deliver your medicines through a validated cold chain shipment process. This process is used as these medicines need to manufactured, transported and stored at very specific temperatures, utilizing thermal and refrigerated packaging methods.

Read more

About GNH

We deliver your medicines through a validated cold chain shipment process. This process is used as these medicines need to manufactured, transported and stored at very specific temperatures, utilizing thermal and refrigerated packaging methods.

We deliver your medicines through a validated cold chain shipment process. This process is used as these medicines need to manufactured, transported and stored at very specific temperatures, utilizing thermal and refrigerated packaging methods.

Read more
  • No data
  • u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS; and SUICIDAL THOUGHTS AND BEHAVIORS
  • Arrayn- Increased Mortality in Elderly Patients with Dementia-Related Psychosis
  • Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death nttttt [n n n . Quetiapine is not approved for the treatment of patients with dementia-related psychosis [n n n n
  • Arrayn- Suicidal Thoughts and Behaviors
  • ntttttt Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term studies. These studies did not show an increase in the risk of suicidal thoughts and behavior with antidepressant use in patients over age 24; there was a reduction in risk with antidepressant use in patients aged 65 and older [n n n . n n n n- In patients of all ages who are started on antidepressant therapy, monitor closely for worsening, and for emergence of suicidal thoughts and behaviors. Advise families and caregivers of the need for close observation and communication with the prescriber [n n n n
  • Quetiapine is not approved for use in pediatric patients under ten years of age [ n n n n
  • nttttttttWARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS; and SUICIDAL THOUGHTS AND BEHAVIORS n n n n n
  • Increased Mortality in Elderly Patients with Dementia-Related Psychosis
  • Suicidal Thoughts and Behaviors
  • Warnings and Precautions, Falls (n n n )u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a002/2017n nn
  • Quetiapine tablet is an atypical antipsychotic indicated for the treatment of:
  • Schizophrenia (n n n n n n )n n n n n n n n n n n n
  • Bipolar I disorder manic episodesnttttttt (n n n n n n )ntttttt n n n n n n n n n n n n
  • Bipolar disorder, depressive episodesnttttttt (n n n n n n )ntttttt n n n n n n n n n n n n
  • Quetiapine tablets can be taken with or without food u00a0 (n n n n n n n n n n n n ).n nn n nn n nn n nn
  • Geriatric Use
  • Hepatic Impairment
  • Tablets: 25 mg, 50 mg, 100 mg, 200 mg, 300 mg, and 400 mg
  • Hypersensitivity to quetiapine or to any excipients in the quetiapine tablets formulation. Anaphylactic reactions have been reported in patients treated with quetiapine tablets.
  • Known hypersensitivity to quetiapine or any components in the formulation.
  • No data
  • Cerebrovascular Adverse Reactions:n- 5.3
  • Neuroleptic Malignant Syndrome (NMS): n- 5.4
  • Metabolic Changes:n- 5.5
  • Hyperglycemia and Diabetes Mellitus:
  • Dyslipidemia:
  • Weight Gain:
  • Tardive Dyskinesia:n- 5.6
  • Hypotension:n- 5.7
  • Increased Blood Pressure in Children and Adolescents:n- 5.9
  • Leukopenia, Neutropenia and Agranulocytosis:n- 5.10
  • Cataracts:n- 5.11
  • The following adverse reactions are discussed in more detail in other sections of the labeling:
  • ntttttttMost common adverse reactions (incidence u22655% and twice placebo):ntttttttAdults: somnolence, dry mouth, dizziness, constipation, asthenia, abdominal pain, postural hypotension, pharyngitis, weight gain, lethargy, ALT increased, dyspepsia (n n n )n nn
  • Children and Adolescents: somnolence, dizziness, fatigue, increased appetite, nausea, vomiting, dry mouth, tachycardia, weight increased (n n n )n nn
  • To report SUSPECTED ADVERSE REACTIONS, contact Accord Healthcare Inc. at 1-866-941-7875 or n n n or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.n n n
  • No data
  • Concomitant use of strong CYP3A4 inhibitors:n- Array
  • Concomitant use of strong CYP3A4 inducers:n- Array
  • Discontinuation of strong CYP3A4 inducers:n- Array
  • No data
  • Pregnancy:n- 8.1
  • Nursing Mothers:n- 8.3
  • No data
  • No data
  • Quetiapine is a psychotropic agent belonging to a chemical class, the dibenzothiazepine derivatives. The chemical designation is 2-[2-(4-dibenzo [n n n n n n n n n n n n ] [1,4]thiazepin-11-yl-1-piperazinyl)ethoxy]-ethanol fumarate (2:1) (salt). It is present in tablets as the fumarate salt. All doses and tablet strengths are expressed as milligrams of base, not as fumarate salt. Its molecular formula is Cn n n n n n n n n n n n Hn n n n n n n n n n n n Nn n n n n n n n n n n n On n n n n n n n n n n n Sn n n n n n n n n n n n u2022Cn n n n n n n n n n n n Hn n n n n n n n n n n n On n n n n n n n n n n n and it has a molecular weight of 883.11 (fumarate salt). The structural formula is:n nn n nn n nn n nn
  • Quetiapine fumarate is a white to off-white crystalline powder which is moderately soluble in water.
  • Quetiapine tablet, USP is supplied for oral administration as 25 mg (round, pink), 50 mg (round, white to off white), 100 mg (round, yellow), 200 mg (round, white to off white), 300 mg (capsule-shaped, white), and 400 mg (capsule-shaped, yellow) tablets.
  • Inactive ingredients are povidone, dibasic calcium phosphate dihydrate, microcrystalline cellulose, sodium starch glycolate, lactose monohydrate, magnesium stearate, hypromellose, polyethylene glycol and titanium dioxide.
  • The 25 mg tablets contain iron oxide red and iron oxide yellow and the 100 mg and 400 mg tablets contain only iron oxide yellow.
  • Each 25 mg tablet contains quetiapine fumarate, USP equivalent to 25 mg quetiapine. Each 50 mg tablet contains quetiapine fumarate, USP equivalent to 50 mg quetiapine. Each 100 mg tablet contains quetiapine fumarate, USP equivalent to 100 mg quetiapine. Each 200 mg tablet contains quetiapine fumarate, USP equivalent to 200 mg quetiapine. Each 300 mg tablet contains quetiapine fumarate, USP equivalent to 300 mg quetiapine. Each 400 mg tablet contains quetiapine fumarate, USP equivalent to 400 mg quetiapine.
  • No data
  • No data
  • No data
  • Product: 63629-4745
  • NDC: 63629-4745-1 1 TABLET, FILM COATED in a BOTTLE
  • See FDA-approved patient labeling (Medication Guide)
  • Prescribers or other health professionals should inform patients, their families, and their caregivers about the benefits and risks associated with treatment with quetiapine and should counsel them in its appropriate use. A patient Medication Guide about u201cAntidepressant Medicines, Depression and other Serious Mental Illness, and Suicidal Thoughts or Actionsu201d is available for quetiapine. The prescriber or health professional should instruct patients, their families, and their caregivers to read the Medication Guide and should assist them in understanding its contents. Patients should be given the opportunity to discuss the contents of the Medication Guide and to obtain answers to any questions they may have. The complete text of the Medication Guide is reprinted at the end of this document.
  • Patients should be advised of the following issues and asked to alert their prescriber if these occur while taking quetiapine.
  • Increased Mortality in Elderly Patients with Dementia-Related Psychosis
  • Patients and caregivers should be advised that elderly patients with dementia-related psychosis treated with atypical antipsychotic drugs are at increased risk of death compared with placebo. Quetiapine is not approved for elderly patients with dementia-related psychosis n n n n
  • Suicidal Thoughts and Behaviors
  • Patients, their families, and their caregivers should be encouraged to be alert to the emergence of anxiety, agitation, panic attacks, insomnia, irritability, hostility, aggressiveness, impulsivity, akathisia (psychomotor restlessness), hypomania, mania, other unusual changes in behavior, worsening of depression, and suicidal ideation, especially early during antidepressant treatment and when the dose is adjusted up or down. Families and caregivers of patients should be advised to look for the emergence of such symptoms on a day-to-day basis, since changes may be abrupt. Such symptoms should be reported to the patient's prescriber or health professional, especially if they are severe, abrupt in onset, or were not part of the patient's presenting symptoms. Symptoms such as these may be associated with an increased risk for suicidal thinking and behavior and indicate a need for very close monitoring and possibly changes in the medicationn n n n n
  • Neuroleptic Malignant Syndrome (NMS)
  • Patients should be advised to report to their physician any signs or symptoms that may be related to NMS. These may include muscle stiffness and high fever n n n n
  • Hyperglycemia and Diabetes Mellitus
  • Patients should be aware of the symptoms of hyperglycemia (high blood sugar) and diabetes mellitus. Patients who are diagnosed with diabetes, those with risk factors for diabetes, or those that develop these symptoms during treatment should have their blood glucose monitored at the beginning of and periodically during treatment n n n n
  • Hyperlipidemia
  • Patients should be advised that elevations in total cholesterol, LDL-cholesterol and triglycerides and decreases in HDL-cholesterol may occur. Patients should have their lipid profile monitored at the beginning of and periodically during treatment n n n n
  • Weight Gain
  • Patients should be advised that they may experience weight gain. Patients should have their weight monitored regularly n n n n
  • Orthostatic Hypotension
  • Patients should be advised of the risk of orthostatic hypotension (symptoms include feeling dizzy or lightheaded upon standing, which may lead to falls), especially during the period of initial dose titration, and also at times of re-initiating treatment or increases in dose n n n n
  • Increased Blood Pressure in Children and Adolescents
  • Children and adolescent patients should have their blood pressure measured at the beginning of, and periodically during, treatment n n n n
  • Leukopenia/Neutropenia
  • Patients with a pre-existing low WBC or a history of drug induced leukopenia/neutropenia should be advised that they should have their CBC monitored while taking quetiapine n n n n
  • Interference with Cognitive and Motor Performance
  • Patients should be advised of the risk of somnolence or sedation (which may lead to falls), especially during the period of initial dose titration. Patients should be cautioned about performing any activity requiring mental alertness, such as operating a motor vehicle (including automobiles) or operating machinery, until they are reasonably certain quetiapine therapy does not affect them adversely n n n n n n n n n n n n n
  • Heat Exposure and Dehydration
  • Patients should be advised regarding appropriate care in avoiding overheating and dehydration n n n n n n n n n n n n n
  • Concomitant Medication
  • As with other medications, patients should be advised to notify their physicians if they are taking, or plan to take, any prescription or over-the-counter drugs n n n n n n n n n n n n n
  • Pregnancy and Nursing
  • Patients should be advised to notify their physician if they become pregnant or intend to become pregnant during therapy with quetiapine n n n n
  • Need for Comprehensive Treatment Program
  • Quetiapine is indicated as an integral part of a total treatment program for adolescents with schizophrenia and pediatric bipolar disorder that may include other measures (psychological, educational, and social). Effectiveness and safety of quetiapine have not been established in pediatric patients less than 13 years of age for schizophrenia or less than 10 years of age for bipolar mania. Appropriate educational placement is essential and psychosocial intervention is often helpful.
  • The decision to prescribe atypical antipsychotic medication will depend upon the physicianu2019s assessment of the chronicity and severity of the patientu2019s symptoms n n n n n n n n n n n n n
  • Manufactured For:n n n n n n n n n n n n n Accord Healthcare, Inc.,n n n n n n n n n n n n n 1009 Slater Road,n n n n n n n n n n n n n Suite 210-B,n n n n n n n n n n n n n Durham, NC 27703,n n n n n n n n n n n n n USA.n nn n nn n nn n nn
  • Manufactured By:
  • Intas Pharmaceuticals Limited,n n n n n n n n n n n n nt Ahmedabad -380 009, India.n n n n n n n n n n n n n
  • 10 0210 1 674302
  • Issued March 2017
  • u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0Medication Guide
  • u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0 u00a0u00a0 u00a0u00a0u00a0u00a0Quetiapine Tablets
  • u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0(kwe-TYE-a-peen)
  • Read this Medication Guide before you start taking quetiapine tablets and each time you get a refill. There may be new information. This information does not take the place of talking to your healthcare provider about your medical condition or your treatment.
  • What is the most important information I should know about quetiapine tablets?
  • Quetiapine tablets may cause serious side effects, including:
  • 1. risk of death in the elderly with dementia:
  • 2. risk of suicidal thoughts or actions (antidepressant medicines, depression and other serious mental illnesses, and suicidal thoughts or actions).
  • Talk to your or your family memberu2019s healthcare provider about:
  • Call a healthcare provider right away if you or your family member has any of the following symptoms, especially if they are new, worse, or worry you:
  • What else do I need to know about antidepressant medicines?
  • What is a quetiapine tablet?
  • It is not known if quetiapine tablet is safe and effective in children under 10 years of age.
  • What should I tell my healthcare provider before taking quetiapine tablets?
  • Before you take quetiapine tablets, tell your healthcare provider if you have or have had:
  • Tell the healthcare provider about all the medicines that you take or recently have taken
  • Quetiapine tablets and other medicines may affect each other causing serious side effects. Quetiapine tablets may affect the way other medicines work, and other medicines may affect how quetiapine tablets works.
  • Tell your healthcare provider if you are having a urine drug screen because quetiapine tablets may affect your test results. Tell those giving the test that you are taking quetiapine tablets.
  • How should I take quetiapine tablets?
  • - If you feel you need to stop quetiapine tablets, talk with your healthcare provider first. If you suddenly stop taking quetiapine tablets, you may have side effects such as trouble sleeping or trouble staying asleep (insomnia), nausea, and vomiting.
  • - If you miss a dose of quetiapine tablets, take it as soon as you remember. If you are close to your next dose, skip the missed dose. Just take the next dose at your regular time. Do not take 2 doses at the same time unless your healthcare provider tells you to. If you are not sure about your dosing, call your healthcare provider.
  • What should I avoid while taking quetiapine tablets?
  • - Do not drive, operate machinery, or do other dangerous activities until you know how quetiapine tablets affects you. Quetiapine tablets may make you drowsy.
  • What are possible side effects of quetiapine tablets?
  • Quetiapine tablets can cause serious side effects, including:
  • u2022 See u201cWhat is the most important information I should know about quetiapine tablets?u201d
  • u2022 stroke that can lead to death can happen in elderly people with dementia who take medicines like quetiapine tablets
  • u2022 neuroleptic malignant syndrome (NMS).
  • u00a0u00a0u00a0u00a0u00a0 o high fever
  • u00a0u00a0u00a0u00a0u00a0 o excessive sweating
  • u00a0u00a0u00a0u00a0u00a0 o rigid muscles
  • u00a0u00a0u00a0u00a0u00a0 o confusion
  • u00a0u00a0u00a0u00a0u00a0 o changes in your breathing, heartbeat, and blood pressure
  • u2022 falls
  • u2022 high blood sugar (hyperglycemia).
  • u00a0u00a0u00a0u00a0u00a0u00a0 o build up of acid in your blood due to ketones (ketoacidosis)
  • u00a0u00a0u00a0u00a0u00a0u00a0 o coma
  • u00a0u00a0u00a0u00a0u00a0u00a0 o death
  • Increases in blood sugar can happen in some people who take quetiapine tablets. Extremely high blood sugar can lead to coma or death. If you have diabetes or risk factors for diabetes (such as being overweight or a family history of diabetes) your healthcare provider should check your blood sugar before you start quetiapine tablets and during therapy.
  • Call your healthcare provider if you have any of these symptoms of high blood sugar (hyperglycemia) while taking quetiapine tablets:
  • u00a0u00a0u00a0u00a0u00a0u00a0 o feel very thirsty
  • u00a0u00a0u00a0u00a0u00a0u00a0 o need to urinate more than usual
  • u00a0u00a0u00a0u00a0u00a0u00a0 o feel very hungry
  • u00a0u00a0u00a0u00a0u00a0u00a0 o feel weak or tired
  • u00a0u00a0u00a0u00a0u00a0u00a0 o feel sick to your stomach
  • u00a0u00a0u00a0u00a0u00a0u00a0 o feel confused, or your breath smells fruity
  • u2022 high fat levels in your blood (increased cholesterol and triglycerides).
  • u2022 increase in weight (weight gain).
  • u2022 movements you cannot control in your face, tongue, or other body parts (tardive dyskinesia).
  • u2022 decreased blood pressure (orthostatic hypotension),
  • u2022 increases in blood pressure in children and teenagers.
  • u2022 low white blood cell count
  • u2022 cataracts
  • u2022 seizures
  • u2022 abnormal thyroid tests:
  • u2022 increases in prolactin levels:
  • u2022 sleepiness, drowsiness, feeling tired, difficulty thinking and doing normal activities
  • u2022 increased body temperature
  • u2022 difficulty swallowing
  • u2022 trouble sleeping or trouble staying asleep (insomnia), nausea, or vomiting if you suddenly stop taking quetiapine tablets.
  • The most common side effects of quetiapine tablets include:
  • In Adults:
  • u2022 dry mouth
  • u2022 constipation
  • u2022 dizziness
  • u2022 sore throat
  • u2022 weakness
  • u2022 difficulty moving
  • u2022 abdominal pain
  • In Children and Adolescents:
  • u2022 nausea
  • u2022 increased appetite
  • u2022 dry mouth
  • u2022 vomiting
  • u2022 weight gain
  • u2022 rapid heart beat
  • These are not all the possible side effects of quetiapine tablets. For more information, ask your healthcare provider or pharmacist.
  • Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
  • How should I store quetiapine tablets?
  • u2022 Store quetiapine tablets at room temperature, between 68u00b0F to 77u00b0F (20u00b0C to 25u00b0C).
  • u2022 Keep quetiapine tablets and all medicines out of the reach of children.
  • General information about the safe and effective use of quetiapine tablets
  • Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use quetiapine tablets for a condition for which it was not prescribed. Do not give quetiapine tablets to other people, even if they have the same symptoms you have. It may harm them.
  • This Medication Guide summarizes the most important information about quetiapine tablets. If you would like more information, talk with your healthcare provider. You can ask your pharmacist or healthcare provider for information about quetiapine tablets that is written for health professionals.
  • For more information, go to www.accordhealthcare.us or call Accord Healthcare Inc. at 1-866-941-7875.n
  • What are the ingredients in quetiapine tablets?
  • Active ingredient:
  • Inactive ingredients:
  • This Medication Guide has been approved by the U.S. Food and Drug Administration.
  • Manufactured For:
  • Accord Healthcare Inc., n n n n n n n n n n n n 1009 Slater Road, n n n n n n n n n n n n Suite 210-B,n n n n n n n n n n n n Durham, NC 27703,n n n n n n n n n n n n USA.n nn n nn n nn n nn
  • Manufactured By:
  • Intas Pharmaceuticals Limited,n n n n n n n n n n n n Ahmedabad -380 009, India.n n n n n n n n n n n n n
  • 10 0210 1 674302
  • Issued March 2017
  • No data

Browse Our Services And Processes

Comparator Sourcing for Clinical Trials

Comparator Sourcing for Clinical Trials

GNH India brings over 10 years of experience in Comparator

Read More

Name Patient Supply

Name Patient Supply

Today, the exact cause for many rare diseases remains unknown

Read More

Validated Cold Chain Shipment

Validated Cold Chain Shipment

With shifting of pharma industry from synthetic molecules to biologic

Read More

Clinical Trials Supply

Clinical Trials Supply

STOP SOURCING..... START SMART SOURCING...... COME STRAIGHT TO THE SOURCE

Read More

Dossiers and Stability Studies

Dossiers and Stability Studies

STABILITY STUDIES STABILITY, BA / BE STUDIES Due to our active

Read More

Pharmaceutical Contract Manufacturing

Pharmaceutical Contract Manufacturing

GNH Provides Contract Manufacturing services for: Generic Medicines with following

Read More

Pricing

Pricing

PRICING POLICY Terms of sales are typically prepaid, unless otherwise

Read More

Disclaimer

Please see the Legal Notice for detailed terms and disclaimers. The Legal Notice governs the use of this Website and by accessing and using this Website you agree to be bound by and accept the Legal Notice.

Browse from other international pharmaceuticals

General

64020 Products

GNH India Brings to over 64036 Product SKUs from India all at 1 place with easy access and global deliveries.

US NDC

71247 Products

GNH India Brings to over 71252 Product SKUs from India all at 1 place with easy access and global deliveries.

Canadian DIN

51046 Products

GNH India Brings to over 51047 Product SKUs from India all at 1 place with easy access and global deliveries.

Swiss Drugs

150 Products

GNH India Brings to over 150 Product SKUs from India all at 1 place with easy access and global deliveries.

NZ Drugs

13296 Products

GNH Brings to over 13298 Product SKUs from India all at 1 place with easy access and global deliveries.

FAQ

Check out our delivery process

Can’t find what
you’re looking for?

Contact US
Pharmexcil
DB
FIEO-2016
SiteLock

Copyright © 2024 GNHIndia .com. All Rights Reserved. Please read Legal Notice for further details.

Disclaimer: Product names, logos, brands and other trademarks featured or referred to are the property of their respective trademark holders.